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A B S T R A C T 
A 55-year-old female presented with history of fever, dry cough and right sided chest pain of two months 
duration. Radiological examination revealed a soft tissue attenuated lesion involving right middle lobe. 
Immuno histochemical analysis leads to the diagnosis of Non Hodgkin’s T-cell Lymphoma. The rarity of 
 this disorder and its good clinical and radiological response to chemotherapy prompted us to report this  
case 
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Introduction: 
Primary pulmonary lymphoma is defined as clonal ly
mphoid proliferation affecting one or both lungs (par
enchyma and/or bronchi) in a patient with no detecta
ble extrapulmonary involvement at diagnosis or durin
g the subsequent 3 months.
1 This is very rare and repr
esent  3-4%  of  extranodal,  less  than  1%  of  non-
 Hodgkin’s  lymphoma    and  only  0.5-
1% of primary pulmonary malignancies.
2 Fifty -eight 
to 87% of cases of this extremely uncommon disease 
are low-grade B-cell lymphomas and 11-19% are hig
h-grade  or  large  B-cell  lymphomas.
3 Non  B-
cell  lymphoma  that  is  ,T  –
cell and natural killer (NK) cell lymphomas  involvin
g the lung parenchyma are rarely reported and the tru
e incidence is unknown.
3 Here we report a case of T –
cell primary pulmonary lymphoma in a 55-year-old f
emale who presented to us  with lung mass. 
 
Case History: 
A 55-year-old non-smoker female was admitted to pu
lmonary medicine department with complaints of fev
er, dry cough and right sided chest pain of two month
s duration. She had normal haematological and bioch
emical parameters. Her admission chest radiograph s
howed a homogeneous mass shadow in the right mid
dle and lower zones [Figure 1]. As chest radiograph 
was inconclusive a computed tomography (CT) of th
orax was done that revealed a large lobulated soft tiss
ue attenuated lesion measuring 10×9.5×8 cm in the ri
ght middle lobe with necrosis [Figure 2]. There was n
o mediastinal or hilar lymph adenopathy. Her sputum 
was negative for both acid fast bacilli as well as for m
alignant cells. Diagnostic bronchoscopy was within n
ormal limits, bronchoalveolar lavage was negative for 
acid fast bacilli and malignant cells and transbronchia
l lung biopsy was inconclusive. Finally, a CT guided 
transthoracic  needle  biopsy  of  the  mass  lesion  was 
performed. The histologic examination of the biopsy 
specimen  showed  tumour  cells  arranged  in  sheets 
with hyperchromatic nuclei with minimal cytoplasm 
and  high  nucleo-cytoplasmic  ratio  [Figure  3]. 
Immunohistochemical  staining  showed  tumour  cell 
positivity for CD3 [Figure 4a] and LCA [Figure 4b], 
negativity for CD20, CD30 and CD56. As CD3 is a 
T-cell marker (CD20 and CD56 are markers of B and 
NK  cells,  respectively)  the  present  malignant 
lymphoma belongs to the T-cell lineage. So, the final  
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pathologic diagnosis was peripheral T-cell lymphoma. 
We  intensely  searched  for  lymphoma  at  other  sites 
and even the bone marrow study was performed but, 
both  of  these  were  normal.  Patient  was  started  on 
systemic  chemotherapy  (CHOP  regimen)  and  after 
four  cycles  of  chemotherapy  patient  showed  good 
clinical  and  radiological  improvement  [Figure  5]. 
Currently she is under our regular follow up. 
 
Discussion:  
Malignant lymphomas may involve the lung in three 
ways:    by  haematogenous  dissemination  of  non-
Hodgkin’s  lymphoma  or  Hodgkin’s  disease,  by 
contiguous invasion from a hilar or mediastinal site 
of  nodal  lymphoma  and  by  primary  pulmonary 
involvement.
3  The  majority  of  the  non-Hodgkin’s 
lymphoma  that  originate  in  the  lung  are  of  B-cell 
lineage. The World Health Organization has divided 
peripheral  T-cell  lymphomas  into  two  main 
categories: precursor T-cell neoplasms, which include 
precursor T-lymphoblastic lymphoma/ leukemia and 
peripheral T-cell neoplasm.
4 There is usually no sex 
predilection and the patient’s age ranges from second 
to ninth decade of life. About half of these patients 
are  asymptomatic  at  presentation.  If  symptoms  are 
present,  usually  these  are  non-specific  with  slight 
predominance  of  respiratory  complaints  such  as 
cough, dyspnoea, chest pain and   hemoptysis.
3 The 
disease  is  most  often  diagnosed  on  radiological 
screening.  The  roentgenographic  appearance  of 
pulmonary lymphoma is usually as an alveolar mass 
or  infiltrate  with  ill  defined  margins  and  air 
bronchograms.
5 For  most  of  the  cases  diagnosis  is 
made by surgical intervention either by thoracotomty 
or  video-assisted  thoracoscopic  surgery,  but  in  our 
case  we  were  able  to  reach  a  diagnosis  by 
transthoracic needle biopsy. The treatment regimens 
for  the  subtypes  of  peripheral  T-cell  lymphoma 
include  CHOP  (cyclophosphamide,  doxorubicin, 
vincristine  and  prednisone)  or  EPOCH  (etoposide 
added to CHOP) based systemic chemotherapy. The 
prognosis  of  peripheral  T-cell  lymphoma  is  poor 
compared  to  B-cell  lymphoma
6  and  the  patients 
usually  succumb  to  life  threatening  complications 
that include infections and hypercalcemia
7. Our case 
was  very  unique  as  it  was  peripheral  T-cell  non 
Hodgkin’s lymphoma presenting as a lung mass with 
central necrosis. There was no disease involvement at 
any other site on the detailed work up and the patient 
showed  good  clinical  and  radiological  response  to 
chemotherapy probably because of early diagnosis of 
disease. 
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Figure  1:  Initial  chest  radiograph  showing 
homogeneous opacity in the right middle and lower 
zone (arrow). 
 
Figure2: Computed tomography showing soft tissue 
attenuated  lesion  in  the  right  middle  lobe  (black 
arrow) measuring 10×9.5×8 cm with necrosis (white 
arrow). 
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Figure 3: Photomicrograph of percutaneous trans thoracic needle biopsy of mass lesion showing round cell tumour 
in sheets with moderate degree of nuclear pleomorphism.  (Hematoxylin and Eosin ×200). 
 
Figure 4: Immunohistochemical staining of tumour cells showing positivity for CD 3 (a) and LCA (b) (Hematoxylin 
and eosin ×100). 
 
Figure 5: Computed tomography obtained after four cycles of chemotherapy showing radiological decrease in size 
of mass lesion (arrows). 
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